Compare
Alaunos Therapeutics, Inc. vs Aditxt, Inc. vs Genelux Corp vs PRF Technologies Ltd.
| Latest fiscal year | Alaunos Therapeutics, Inc. TCRT | Aditxt, Inc. ADTX | Genelux Corp GNLX | PRF Technologies Ltd. PRFX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $5.0K | $3.2K | $8.0K | $17.0K |
| Revenue growth (YoY) | -50.0% | -97.6% | 0.0% | n/a |
| Gross margin | n/a | 8.4% | n/a | -311.8% (computed) |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$4.18M | -$43.10M | -$32.15M | -$5.02M |
| EPS (Diluted) | -$2.20 | -$1153.83 | -$0.86 | -$7.47 |
| Operating cash flow | -$2.87M | -$25.69M | -$25.27M | -$3.96M |
| Free cash flow | -$2.97M | -$25.70M | -$26.37M | -$3.96M |
| Cash & equivalents | $1.39M | n/a | $5.33M | $3.12M |
| Total assets | $2.97M | $16.52M | $19.03M | $12.00M |
| Total liabilities | $813.0K | $12.56M | $7.48M | $2.71M |
| Shareholders' equity | $2.15M | $5.61M | $11.54M | $8.54M |
| Return on year-end equity | -194.0% | -768.3% | -278.5% | -58.8% |
| Shares outstanding | 2.35M | 411.5K | 38.14M | 830.6K |
Revenue, most recent five fiscal years
| Fiscal year | Alaunos Therapeutics, Inc. | Aditxt, Inc. | Genelux Corp | PRF Technologies Ltd. |
|---|---|---|---|---|
| Latest | $5.0K Ended 2025-12-31 | $3.2K Ended 2025-12-31 | $8.0K Ended 2025-12-31 | $17.0K Ended 2025-12-31 |
| 1 year earlier | $10.0K Ended 2024-12-31 | $134.0K Ended 2024-12-31 | $8.0K Ended 2024-12-31 | $0 Ended 2024-12-31 |
| 2 years earlier | $5.0K Ended 2023-12-31 | $645.2K Ended 2023-12-31 | $170.0K Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | $2.92M Ended 2022-12-31 | $933.7K Ended 2022-12-31 | $11.07M Ended 2022-12-31 | n/a |
| 4 years earlier | $398.0K Ended 2021-12-31 | $105.0K Ended 2021-12-31 | n/a | n/a |